Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on April 8, 2022, reporting events occurring on April 5, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Deer Park, Illinois. Its common stock trades on the NASDAQ Global Market under the symbol "ETON."
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. The report focuses exclusively on a material amendment to the Company's existing Credit Agreement with SWK Holdings Corporation.
Material Changes
On April 5, 2022, the Company amended its Credit Agreement dated November 13, 2019. The amendment includes the following material changes:
- Interest Rate Reduction: The base interest rate was reduced from LIBOR 3-month plus 10.0% to LIBOR 3-month plus 8.0%, subject to a LIBOR floor rate of 2.0%.
- Payment Deferral: Additional loan principal payments have been deferred until May 15, 2023.
- Prepayment Fee Extension: The 1% loan prepayment fee period was extended from May 13, 2023, to May 13, 2024.
All other terms and conditions of the Credit Agreement remain unchanged.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the terms of the amended credit facility.
Key Facts for Investor Verification
- Verify the impact of the reduced interest rate (200 basis point reduction) on future interest expense.
- Confirm the deferral of principal payments extends liquidity runway until May 2023.
- Note the extended prepayment fee period, which may impact refinancing flexibility until May 2024.
- Review the full Credit Agreement to understand the LIBOR floor implications given current market rates.